MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
39.83
-0.67
-1.65%
Opening 14:42 02/11 EST
OPEN
40.75
PREV CLOSE
40.50
HIGH
40.84
LOW
39.19
VOLUME
438.61K
TURNOVER
--
52 WEEK HIGH
90.32
52 WEEK LOW
37.95
MARKET CAP
2.14B
P/E (TTM)
-21.6315
1D
5D
1M
3M
1Y
5Y
1D
Soleno Therapeutics Inc. published an update to their financial calendar
Reuters · 6h ago
Weekly Report: what happened at SLNO last week (0202-0206)?
Weekly Report · 2d ago
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
Benzinga · 02/02 15:44
Weekly Report: what happened at SLNO last week (0126-0130)?
Weekly Report · 02/02 10:33
Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating
TipRanks · 01/29 13:35
Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)
TipRanks · 01/29 13:15
Soleno Therapeutics to Present at Major Biotech and Healthcare Conferences
Reuters · 01/29 13:00
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO)
TipRanks · 01/27 13:50
More
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.